Applied Therapeutics, Inc. (APLT) NASDAQ

0.35

-0.0265(-7.09%)

Updated at June 26 11:33AM

Currency In USD

Applied Therapeutics, Inc.

Address

545 Fifth Avenue

New York City, NY 10017

United States of America

Phone

212 220 9226

Sector

Healthcare

Industry

Biotechnology

Employees

35

First IPO Date

May 14, 2019

Key Executives

NameTitlePayYear Born
Mr. Les D. FuntleyderInterm Chief Executive Officer, Chief Financial Officer, Principal Financial Officer & Director768,8461970
Mr. John H. JohnsonExecutive Chairman378,8401958
Mr. Corwin Dale HooksChief Commercial Officer636,7391967
Dr. Riccardo Perfetti M.D., Ph.D.Chief Medical Officer860,7611960
Mr. Constantine ChinoporosChief Operating Officer & Chief Business Officer01966
Dr. Todd F. Baumgartner M.D., M.P.H.Chief Regulatory Officer0N/A
Ms. Reena Thomas ColacotHead of Quality0N/A
Ms. Catherine ThorpeInterim Chief Accounting Officer01964

Description

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.